Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
26.61 (1y: +45%)
Market Cap 2.16 B P/E(ttm)
Enterprise Value 6.29 B P/B 1.00
ALR- NYSE (USA)
Alere Inc
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$26.61
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash to Debt 0.086
ALR's Cash to Debt is ranked lower than
89% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.56 vs. ALR: 0.086 )
ALR' s 10-Year Cash to Debt Range
Min: 0.09   Max: 1.68
Current: 0.09
0.09
1.68
Equity to Asset -0.387
ALR's Equity to Asset is ranked lower than
93% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.50 vs. ALR: -0.387 )
ALR' s 10-Year Equity to Asset Range
Min: -0.39   Max: 0.24
Current: -0.39
-0.39
0.24
Interest Coverage 0.5
ALR's Interest Coverage is ranked lower than
72% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 66.20 vs. ALR: 0.5 )
ALR' s 10-Year Interest Coverage Range
Min: 0   Max: 3
Current: 0.5
0
3
F-Score: 3
Z-Score: 0.3
M-Score: -2.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry		 vs
history
Operating margin (%) 3.90
ALR's Operating margin (%) is ranked higher than
56% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. ALR: 3.90 )
ALR' s 10-Year Operating margin (%) Range
Min: -44.1   Max: 11.4
Current: 3.9
-44.1
11.4
Net-margin (%) -2.8
ALR's Net-margin (%) is ranked lower than
53% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. ALR: -2.8 )
ALR' s 10-Year Net-margin (%) Range
Min: -50.1   Max: 6.2
Current: -2.8
-50.1
6.2
ROE (%) -3.6
ALR's ROE (%) is ranked lower than
51% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.00 vs. ALR: -3.6 )
ALR' s 10-Year ROE (%) Range
Min: -39.5   Max: 8.8
Current: -3.6
-39.5
8.8
ROA (%) -1.1
ALR's ROA (%) is ranked lower than
53% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. ALR: -1.1 )
ALR' s 10-Year ROA (%) Range
Min: -16.1   Max: 5
Current: -1.1
-16.1
5
ROC (Joel Greenblatt) (%) 9.60
ALR's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.00 vs. ALR: 9.60 )
ALR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -227.8   Max: 86.3
Current: 9.6
-227.8
86.3
Revenue Growth (%) 10.5
ALR's Revenue Growth (%) is ranked higher than
79% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. ALR: 10.5 )
ALR' s 10-Year Revenue Growth (%) Range
Min: -4.6   Max: 29
Current: 10.5
-4.6
29
EBITDA Growth (%) 5.9
ALR's EBITDA Growth (%) is ranked higher than
63% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.85 vs. ALR: 5.9 )
ALR' s 10-Year EBITDA Growth (%) Range
Min: -32.4   Max: 67
Current: 5.9
-32.4
67
ยป ALR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

ALR Guru Trades in Q2 2012

Paul Tudor Jones 12,000 sh (New)
Private Capital 1,734,463 sh (+35.93%)
Diamond Hill Capital 833,850 sh (+20.22%)
Manning & Napier Advisors, Inc 9,842,458 sh (+10.6%)
Pioneer Investments 74,600 sh (unchged)
Jim Simons Sold Out
Steven Cohen Sold Out
Seth Klarman Sold Out
Mario Gabelli 10,000 sh (-25.93%)
Jeremy Grantham 146,500 sh (-33.47%)
» More
Q3 2012

ALR Guru Trades in Q3 2012

Steven Cohen 1,095,953 sh (New)
Private Capital 1,776,220 sh (+2.41%)
Manning & Napier Advisors, Inc 9,852,438 sh (+0.1%)
Pioneer Investments 74,600 sh (unchged)
Mario Gabelli 10,000 sh (unchged)
Paul Tudor Jones Sold Out
Diamond Hill Capital 826,850 sh (-0.84%)
Jeremy Grantham 120,400 sh (-17.82%)
» More
Q4 2012

ALR Guru Trades in Q4 2012

Chuck Royce 409,000 sh (New)
Pioneer Investments 74,600 sh (unchged)
Mario Gabelli 10,000 sh (unchged)
Jeremy Grantham 154,612 sh (unchged)
Manning & Napier Advisors, Inc 9,449,183 sh (-4.09%)
Private Capital 1,653,748 sh (-6.9%)
Diamond Hill Capital 742,760 sh (-10.17%)
Steven Cohen 140,712 sh (-87.16%)
» More
Q1 2013

ALR Guru Trades in Q1 2013

Jim Simons 408,224 sh (New)
Chuck Royce 568,500 sh (+39%)
Diamond Hill Capital 791,005 sh (+6.5%)
Jeremy Grantham 154,756 sh (+0.09%)
Pioneer Investments 74,600 sh (unchged)
Mario Gabelli 10,000 sh (unchged)
Private Capital 1,618,623 sh (-2.12%)
Manning & Napier Advisors, Inc 9,196,270 sh (-2.68%)
Steven Cohen 41,342 sh (-70.62%)
» More
» Details

Insider Trades

Latest Guru Trades with ALR

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Seth Klarman 2012-06-30 Sold Out 0.12%$17.98 - $25.97 $ 26.5327%0
Mario Gabelli 2012-06-30 Reduce -25.93%$17.98 - $25.97 $ 26.5327%10000
Seth Klarman 2012-03-31 Reduce -93.12%1.3%$22.21 - $26.64 $ 26.5316%137700
Seth Klarman 2011-12-31 Reduce -35.48%0.72%$18.51 - $26.43 $ 26.5315%2000000
David Dreman 2011-12-31 Sold Out 0.53%$18.51 - $26.43 $ 26.5315%0
Mario Gabelli 2011-12-31 Reduce -27.03%$18.51 - $26.43 $ 26.5315%13500
George Soros 2011-06-30 Sold Out $33.98 - $41 $ 26.53-30%0
Mario Gabelli 2011-03-31 Reduce -77.58%0.03%$36.17 - $40.32 $ 26.53-31%18500
George Soros 2011-03-31 Reduce -29.29%$36.17 - $40.32 $ 26.53-31%14000
Seth Klarman 2010-12-31 Add 106.67%3.38%$28.14 - $36.39 $ 26.53-16%3100000
George Soros 2010-12-31 Add 45.59%$28.14 - $36.39 $ 26.53-16%19800
Seth Klarman 2010-09-30 New Buy2.81%$26.5 - $31.29 $ 26.53-9%1500000
David Dreman 2010-09-30 New Buy0.76%$26.5 - $31.29 $ 26.53-9%1067385
George Soros 2010-09-30 New Buy0.01%$26.5 - $31.29 $ 26.53-9%13600
Mario Gabelli 2010-09-30 New Buy0.01%$26.5 - $31.29 $ 26.53-9%82500
Premium More recent guru trades are included for Premium Members only!!

Preferred stocks of Alere Inc

SymbolPriceYieldDescription
ALRPRB6.744.85

Ratios

vs
industry		 vs
history
P/B 1.00
ALR's P/B is ranked higher than
86% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. ALR: 1.00 )
ALR' s 10-Year P/B Range
Min: 0.34   Max: 2.39
Current: 1
0.34
2.39
P/S 0.70
ALR's P/S is ranked higher than
84% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. ALR: 0.70 )
ALR' s 10-Year P/S Range
Min: 0.52   Max: 9.71
Current: 0.7
0.52
9.71
PFCF 21.70
ALR's PFCF is ranked higher than
78% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.30 vs. ALR: 21.70 )
ALR' s 10-Year PFCF Range
Min: 7.62   Max: 135.97
Current: 21.7
7.62
135.97
EV-to-EBIT 58.8
ALR's EV-to-EBIT is ranked higher than
56% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.90 vs. ALR: 58.8 )
ALR' s 10-Year EV-to-EBIT Range
Min: 6.5   Max: 2833.4
Current: 58.8
6.5
2833.4

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 4.3
ALR's Price/Net Current Asset Value is ranked lower than
56% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.40 vs. ALR: 4.3 )
ALR' s 10-Year Price/Net Current Asset Value Range
Min: 3   Max: 53.1
Current: 4.3
3
53.1
Price/DCF (Projected) 0.6
ALR's Price/DCF (Projected) is ranked higher than
68% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. ALR: 0.6 )
ALR' s 10-Year Price/DCF (Projected) Range
Min: 0.4   Max: 2.5
Current: 0.6
0.4
2.5
Price/Median PS Value 0.5
ALR's Price/Median PS Value is ranked lower than
57% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.90 vs. ALR: 0.5 )
ALR' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 2.5
Current: 0.5
0.4
2.5
Earnings Yield (Greenblatt) 1.70
ALR's Earnings Yield (Greenblatt) is ranked higher than
63% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.60 vs. ALR: 1.70 )
ALR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 15.3
Current: 1.7
0.3
15.3
Forward Rate of Return (Yacktman) 5.68
ALR's Forward Rate of Return (Yacktman) is ranked higher than
92% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.46 vs. ALR: 5.68 )
ALR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -22.6   Max: 9.4
Current: 5.68
-22.6
9.4

Business Description

Alere Inc, formerly known as Inverness Medical Innovations, Inc. is a Delaware corporation, which was formed to acquire the women's health, nutritional supplements and professional diagnostics businesses of its predecessor, Inverness Medical Technology, Inc., through a split-off and merger transaction, which occurred in November 2001. The Company enables individuals to take charge of improving their health and quality of life at home by developing new capabilities in near-patient diagnosis, monitoring and health management. The Company's global products and services, as well as its new product development efforts, focuses on cardiology, infectious disease, toxicology, diabetes, oncology and women's health. The Company's main reportable operating segments are professional diagnostics, health management and consumer diagnostics. Professional diagnostics are generally designed to assist medical professionals in both preventative and interventional medicine, and include testing and monitoring performed in hospitals and doctors' offices and, increasingly, testing and monitoring done at home at the direction of the medical professional, or through patient self-testing. Professional diagnostic products provide for qualitative or quantitative analysis of a patient's body fluids or tissue for evidence of a specific medical condition, disease state or toxicological state or to measure response to therapy. The Company's health management business strives to empower participants of its programs and physicians so they could work together towards better health. It also provides services supporting home INR testing. Its health management business is principally conducted in the United States. The Company's other current consumer diagnostic products consist of its market-leading First Check brand of over-the-counter drugs of abuse tests for at-home testing for up to seven illicit drugs and five prescription drugs, as well as First Check brand over-the-counter tests for alcohol abuse, cholesterol monitoring and colon cancer screening. The Company's manufacturing facilities are located in San Diego, California; Scarborough, Maine; Dundee, Scotland; Oslo, Norway; Hangzhou and Shanghai, China; Matsudo, Japan; and Yongin, South Korea. It also manufactures products at a number of other facilities in the United States, Australia, Germany, India, Israel, South Africa, Spain and the United Kingdom. Its competitors in the United States and abroad are numerous and include, among others, diagnostic testing and medical products companies, universities and other research institutions, health management service providers, healthcare providers and health insurers. The main competitors for its professional rapid diagnostic products are Becton Dickinson, Quidel and Meridian Bioscience. The Company's businesses are subject to frequently changing federal, state, local and foreign laws and regulations.
Company Website
SEC Reports
Industry: Diagnostics & Research
Compare:LH, DGX, LIFE, ENZ, IDXX
Traded in other countries:IM5.Germany
ยป More Articles for ALR

Headlines

Articles On GuruFocus.com
Microcap Man Chuck Royce Reveals Top New Stock Buys Feb 07 2013 
Coach and Ralph Lauren Earnings Exposed to Yen Volatility Jan 10 2013 
Diamond Hill Capital Buys Comcast Corp, Walt Disney, Alere Inc, Alaska Air Grp, Xl Group, CareFusion Apr 19 2012 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Seth Klarman Latest Portfolio: Buys IDIX, NG, ANV, Sells PDLI, ALR, BBEP Feb 10 2012 
Are Regional Banks Free from European Exposure? Jan 27 2012 
Alere Inc.: Foreign Currency Translations and the Euro Dec 21 2011 
Diamond Hill Capital's Top 5 Third Quarter New Buys Oct 21 2011 
Diamond Hill Capital Q3 Portfolio Update Oct 20 2011 
Seth Klarman's Top 5 Picks: VSAT, THRX, NWS, CSE, ALR Mar 11 2011 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial